<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080613</url>
  </required_header>
  <id_info>
    <org_study_id>NU-02B4</org_study_id>
    <secondary_id>CDR0000346457</secondary_id>
    <nct_id>NCT00080613</nct_id>
  </id_info>
  <brief_title>Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant and Adjuvant Exemestane in Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert H. Lurie Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen and progesterone can stimulate the growth of breast cancer cells. Hormone&#xD;
      therapy using exemestane may fight breast cancer by reducing the production of estrogen and&#xD;
      progesterone. Giving hormone therapy before surgery may shrink the tumor so it can be removed&#xD;
      with breast-conserving surgery. Giving hormone therapy after surgery may kill any remaining&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of neoadjuvant and adjuvant exemestane in&#xD;
      treating postmenopausal women who have locally advancedestrogen and/or progesterone&#xD;
      receptor-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical response rate in postmenopausal women with locally advanced&#xD;
           hormone receptor-positive breast cancer treated with neoadjuvant and adjuvant&#xD;
           exemestane.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate by mammography, ultrasound, MRI, and positron emission&#xD;
           tomography scan in patients treated with this drug.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this drug.&#xD;
&#xD;
        -  Compare the expression of hormone receptors and epidermal growth factor receptors&#xD;
           (including HER2/neu) in patients prior to and after treatment with this drug and&#xD;
           correlate these results with clinical response rates.&#xD;
&#xD;
      OUTLINE: Patients receive oral exemestane once daily for 16 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity. After 16 weeks, patients undergo surgery and then&#xD;
      continue exemestane once daily for a total of 5 years (including the 16 weeks before&#xD;
      surgery).&#xD;
&#xD;
      Patients are followed every 3 months for 2 years after surgery and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-46 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aromatase inhibition</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hormone therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
          -  Locally advanced disease (stage II or III)&#xD;
&#xD;
          -  Not amenable to breast-conserving therapy at the time of diagnosis&#xD;
&#xD;
          -  Measurable disease meeting 1 of the following criteria:&#xD;
&#xD;
          -  Bidimensionally measurable palpable lesion at least 1 cm by caliper&#xD;
&#xD;
          -  Unidimensionally measurable lesion at least 1 cm by a positive mammogram, ultrasound,&#xD;
             or MRI&#xD;
&#xD;
          -  No evidence of disease outside the breast or chest wall except ipsilateral axillary&#xD;
             lymph nodes&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
          -  Estrogen and/or progesterone receptor positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined as any of the following:&#xD;
&#xD;
          -  Over 60 years of age&#xD;
&#xD;
          -  Over 45 years of age with an intact uterus and amenorrhea for more than 12 months&#xD;
&#xD;
          -  Prior hysterectomy with follicle-stimulating hormone levels within the postmenopausal&#xD;
             range&#xD;
&#xD;
          -  Prior ovarian ablation (i.e., bilateral surgical)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior or concurrent cancer except nonmetastatic nonmelanoma skin cancer,&#xD;
             carcinoma in situ of the cervix, or cancer cured by surgery within the past 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy for breast cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for breast cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for breast cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William John Gradishar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

